Follica Moves Forward, Thorn Medical: Weekly Thoughts 4/17/16

Hey there everybody, nice to see you all again. In this edition of Weekly Thoughts we find a new company with some ambiguous, yet noteworthy, claims about their hair growth technology, an update on Follica’s new pivot, and some background information on Samumed’s founder and CEO. Thorn Medical Makes Big Claim Last week, a press…

Read More

How to React to the Announcement of a New Treatment?

Originally published April 8, 2016 This is a discussion that I have planned to do for a while now. After reading about a new hair growth treatment that was announced yesterday, and knowing I would soon be sharing it with you all, I decided it was time to write this article first. When writing these…

Read More

Vixen Pharmaceuticals Acquired By Aclaris Therapeutics

Well you guys asked for it, right? An established pharmaceutical company has acquired the rights to Angela Christiano’s hair growth research involving JAK inhibitors. Aclaris Therapeutics has entered into an agreement with Vixen to acquire all of the stock of Vixen Pharmaceuticals. For those unaware, Vixen Pharma is the small startup company that Christiano founded…

Read More

Yeditepe University Hair Growth Cream

A research team from Yeditepe University in Turkey recently announced that they will be launching a hair growth cream within the next two months. The team is headed by Prof. Fikrettin Sahin, head of the Department of Genetics and Bioengineering at Yeditepe University. The news was made public last Friday during a press conference that…

Read More

What About Samumed Phase II?

What is most significant and encouraging about this new data is the SM04554 treatment was applied for only 90 days, but continued to have positive results all the way until 135 days. The chart shows that during the 45 days after the treatment was stopped, there was still a continual increase in hair count from…

Read More

Samumed to Release Phase 2 Results at AAD

An important bit of news surfaced online this weekend about the company Samumed and their heralded phase 2 results. Samumed will be presenting “Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial” on March 5th, 2016 at the 74th Annual Meeting of the American Academy…

Read More

COL17A1, Foxc1, Brotzu: Weekly Thoughts 2/8/16

Hello everybody, nice to be back here with you again. There seems to have been a surge of hair growth related news as of late which makes it a great time to do some reporting. Without further ado, here are your Weekly Thoughts. COL17A1 and Hair Follicle Aging A major key to understanding the process…

Read More